Group 1 - Lichong Group expects a net profit of 830 million to 870 million yuan for 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - Shandong Zhanggu anticipates a net profit of 72 million to 80 million yuan for 2025, with a year-on-year increase of 0.65% to 11.83% [2] - Yinglian Co. forecasts a net profit of 32 million to 42 million yuan for 2025, marking a turnaround from a loss of 39.67 million yuan in the previous year [3] Group 2 - Hangya Technology announces plans for shareholders to reduce their holdings by up to 2.76% of the company's shares [4] - Guizhou Tire plans to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [5] - Laisentongling's shareholder plans to reduce their stake by no more than 1% [6] Group 3 - ST Yifei's shareholder intends to reduce their holdings by up to 1.53% [7] - Hengyi Petrochemical has fully launched the second phase of its Brunei refining project, aiming for a production capacity of 12 million tons per year [8] - Zai Sheng Technology's controlling shareholder has terminated an agreement to transfer part of the company's shares [9] Group 4 - Sry New Materials proposes a cash dividend of 0.4 yuan per 10 shares for the first three quarters of 2025 [10] - Quanyin High-Tech announces that the offer period for China Seed Group's acquisition has expired, leading to a temporary suspension of its stock [11] - Zhonggang Luonai's shareholder plans to reduce their stake by up to 1% [12] Group 5 - Nanmo Bio expects to receive a government subsidy of 5.8 million yuan for its subsidiary [13] - Beite Technology has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [14] - Qianyuan Pharmaceutical's subsidiary has obtained drug registration certificates for a new medication [15] Group 6 - Boto Integrated plans to reduce its holdings by no more than 1% [16] - Wanze Co. intends to reduce its stake by up to 1.66% [17] - Tianci Materials will halt production for maintenance on its lithium hexafluorophosphate production line starting March 1, 2026 [18] Group 7 - Haopeng Technology plans to raise up to 800 million yuan through a private placement [20] - Yisheng Co. reports a 43.32% year-on-year increase in sales revenue for its white feather broiler chicks in December 2025 [21] - Jinyu Medical proposes a cash dividend of 8.8 yuan per 10 shares for the first three quarters of 2025 [22] Group 8 - Caesar Travel's subsidiary has won a management service project for the Qingdao International Cruise Port [23] - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan [24] - Jiangling Motors reports a 10.56% year-on-year increase in cumulative sales for 2025 [25] Group 9 - Yilian Technology plans to issue convertible bonds to raise up to 1.2 billion yuan [26] - Shaanxi Guotou A intends to participate in a capital increase for Chang'an Bank, with an amount not exceeding 800 million yuan [27] - Oupokang Vision has obtained a production license for eye drops [28] Group 10 - Shanghai Electric plans to provide management services for overseas assets of China Electric International [30] - Yingfang Micro is planning a major asset restructuring, leading to a temporary suspension of its stock [31] - Victory Energy's stock will resume trading after completing a verification process [32] Group 11 - China Merchants Industry has signed a shipbuilding agreement with Dalian Shipbuilding [33] - Kunyu Group has appointed a new chairman following a board meeting [34] - Microchip Bio's clinical trial application for a new diabetes treatment has been accepted [35] Group 12 - Hanshuo Technology has signed a sales intention agreement for smart shopping carts with Woolworths in Australia [36] - Zhongmin Energy's three photovoltaic power station projects have been included in the Fujian Province development list [37] - Penghui Energy plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [38] Group 13 - Victory Energy reports that the acquirer has deposited a guarantee for the acquisition [39] - Fangsheng Pharmaceutical proposes a special dividend of 0.15 yuan per share for 2025 [40] - Nanning Department Store has received approximately 14.28 million yuan in government subsidies since January 2025 [41] Group 14 - Jushen Co. has signed a bauxite transfer agreement with a company in Guinea [42] - ST Huluwawa has received a drug registration certificate for a new inhalation solution [43] - Zhongzhi Co. will become the controlling shareholder following a share transfer agreement [44] Group 15 - Chuangli Group has signed a strategic cooperation framework agreement with Chuanjiu Construction [45]

两融数据显示，该股最新融资余额为6134.82万元，近5日减少233.77万元，降幅为3.67%。（数据宝） 1月5日南模生物大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日收 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额（万 | 格 | 盘折溢价 | 买方营业部 | 卖方营业部 | | 股） | 元） | （元） | （%） | | | | | | | | 国泰海通证券股份有限公司 | 信达证券股份有限公司上 | | 6.31 | 299.91 | 47.53 | 8.17 | 上海静安区南京西路证券营 | 海浦东新区源深路证券营 | | | | | | 业部 | 业部 | （文章来源：证券时报网） 南模生物1月5日大宗交易平台出现一笔成交，成交量6.31万股，成交金额299.91万元，大宗交易成交价 为47.53元，相对今日收盘价溢价8.17%。该笔交易的买方营业部为国泰海通证券股份有限公司上海静安 区南京西路证券营业部，卖方营业部为信达证券股份有限公司上海浦东新区源深路证券营业部。 证券时报·数据宝统计显示，南模生物今日收盘价为4 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 南模生物(688265.SH)公告称，公司的全资子公司上海砥石生物科技有限公司近期与上海市金山区科学 技术委员会签订了《上海张江国家自主创新示范区专项发展资金项目管理合同》，预计获得580万元政 府补助，其中与资产相关的政府补助290万元，占公司最近一个会计年度经审计总资产的比例为 0.15%；与收益相关的政府补助290万元，占公司最近一个会计年度经审计净利润的比例为44.65%。截 至本公告披露日，上述补助资金尚未到账。 ...

Group 1 - The company, Nanmo Biology (688265), announced on January 5 that its wholly-owned subsidiary, Shanghai Dishi Biotechnology Co., Ltd., signed a project management contract with the Shanghai Jinshan District Science and Technology Commission to receive a government subsidy of 5.8 million yuan [1] - The government subsidy includes 2.9 million yuan related to assets, which accounts for 0.15% of the company's total audited assets for the most recent fiscal year [1] - The subsidy also includes 2.9 million yuan related to income, representing 44.65% of the company's audited net profit for the most recent fiscal year [1] - As of the date of the announcement, the subsidy funds have not yet been received [1]

证券代码：688265 证券简称：南模生物 公告编号：2026-001 上海南方模式生物科技股份有限公司 关于子公司获得政府补助的公告 一、获得补助的基本情况 上海南方模式生物科技股份有限公司（以下简称"公司"）的全资子公司上海 砥石生物科技有限公司近期与上海市金山区科学技术委员会签订了《上海张江国 家自主创新示范区专项发展资金项目管理合同》，预计获得 580 万元政府补助， 其中与资产相关的政府补助 290 万元，占公司最近一个会计年度经审计总资产的 比例为 0.15%；与收益相关的政府补助 290 万元，占公司最近一个会计年度经审 计净利润的比例为 44.65%。截至本公告披露日，上述补助资金尚未到账。公司 收到相关的补助资金后，将根据《企业会计准则第 16 号——政府补助》的规定， 在实际发生时根据支付对象，按照会计准则进行相应的账务处理。 二、补助的类型及其对公司的影响 根据《企业会计准则第 16 号——政府补助》的有关规定，确认上述事项并 划分补助类型。上述政府补助未经审计，具体的会计处理及对公司损益的影响， 最终以审计机构年度审计确认后的结果为准，敬请投资者注意投资风险。 特此公告。 上海南方模式 ...

Group 1 - The company, Shanghai Nanmo Biological, announced that its wholly-owned subsidiary, Shanghai Dish Biotech, signed a contract with the Shanghai Jinshan District Science and Technology Committee to receive a government subsidy of 5.8 million yuan [1] - The government subsidy includes 2.9 million yuan related to assets, which accounts for 0.15% of the company's audited total assets for the most recent fiscal year [1] - The subsidy also includes 2.9 million yuan related to income, representing 44.65% of the company's audited net profit for the most recent fiscal year [1] - As of the date of the announcement, the subsidy funds have not yet been received [1]

Core Viewpoint - Nanmo Bio (688265.SH) has signed a project management contract with the Shanghai Jinshan District Science and Technology Commission, expecting to receive a government subsidy of 5.8 million yuan [1] Group 1: Government Subsidy Details - The government subsidy includes 2.9 million yuan related to assets, which accounts for 0.15% of the company's audited total assets for the most recent fiscal year [1] - The subsidy also includes 2.9 million yuan related to income, representing 44.65% of the company's audited net profit for the most recent fiscal year [1] - As of the date of the announcement, the subsidy funds have not yet been received [1]

Core Viewpoint - Nanmo Bio (688265.SH) has signed a project management contract with the Shanghai Jinshan District Science and Technology Commission, expecting to receive a government subsidy of 5.8 million yuan [1] Group 1: Government Subsidy Details - The government subsidy includes 2.9 million yuan related to assets, which accounts for 0.15% of the company's audited total assets for the most recent fiscal year [1] - The subsidy also includes 2.9 million yuan related to income, representing 44.65% of the company's audited net profit for the most recent fiscal year [1] - As of the date of the announcement, the subsidy funds have not yet been received [1]

Group 1 - The core transaction of Nanmo Biology involved a block trade of 63,100 shares, with a total transaction value of 2.9991 million yuan, accounting for 4.21% of the total trading volume on that day [1] - The transaction price was 47.53 yuan, which represents a premium of 8.17% compared to the market closing price of 43.94 yuan [1]

Group 1 - The core viewpoint of the articles highlights the recent stock performance and financial results of Nanmo Biological, indicating a slight increase in stock price and significant growth in revenue and net profit [1][2] - As of January 5, Nanmo Biological's stock price rose by 2.07% to 41.86 CNY per share, with a total market capitalization of 3.264 billion CNY [1] - The company has experienced a year-to-date stock price increase of 2.07%, with a 14.29% year-on-year revenue growth of 303 million CNY for the period from January to September 2025 [1] Group 2 - Nanmo Biological's main business involves the research, production, and sales of genetically modified animal models, with revenue contributions from standardized models (48.34%), model technical services (21.92%), breeding (19.50%), and customized models (9.34%) [1] - The company has distributed a total of 30.0413 million CNY in dividends since its A-share listing, with 10.0047 million CNY in the last three years [2] - As of September 30, 2025, the number of shareholders increased by 2.53% to 6,687, while the average circulating shares per person decreased by 2.47% to 11,658 shares [1]